186 related articles for article (PubMed ID: 1283356)
1. Treatment of AIDS-related non-Hodgkin's lymphoma with a twelve week chemotherapy program.
Sawka CA; Shepherd FA; Brandwein J; Burkes RL; Sutton DM; Warner E
Leuk Lymphoma; 1992 Oct; 8(3):213-20. PubMed ID: 1283356
[TBL] [Abstract][Full Text] [Related]
2. MACOP-B chemotherapy for the treatment of high-grade lymphomas in patients with HIV-1 infection.
Taillan B; Garnier G; Ferrari E; Pesce A; Vinti H; Fuzibet JG; Dujardin P
Acta Haematol; 1993; 89(1):10-2. PubMed ID: 7683165
[TBL] [Abstract][Full Text] [Related]
3. A prospective, non-randomised phase 1-2 trial of VACOP-B with filgrastim support for HIV-related non-Hodgkin's lymphoma.
Sawka CA; Shepherd FA; Franssen E; Brandwein J; Dotten DA; Routy JP; Walker IR; St-Louis J; Taylor M; Arts K; Crump M; Foote M
Biotechnol Annu Rev; 2005; 11():381-9. PubMed ID: 16216784
[TBL] [Abstract][Full Text] [Related]
4. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
Fisher RI; Gaynor ER; Dahlberg S; Oken MM; Grogan TM; Mize EM; Glick JH; Coltman CA; Miller TP
N Engl J Med; 1993 Apr; 328(14):1002-6. PubMed ID: 7680764
[TBL] [Abstract][Full Text] [Related]
5. Low dose methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine, and dexamethasone with zalcitabine in patients with acquired immunodeficiency syndrome-related lymphoma. Effect on human immunodeficiency virus and serum interleukin-6 levels over time.
Levine AM; Tulpule A; Espina B; Boswell W; Buckley J; Rasheed S; Stain S; Parker J; Nathwani B; Gill PS
Cancer; 1996 Aug; 78(3):517-26. PubMed ID: 8697399
[TBL] [Abstract][Full Text] [Related]
6. The MACOP-B and VACOP-B combination chemotherapy for young patients with intermediate-grade non-Hodgkin's lymphoma.
Dreiher J; Shpilberg O; Raanani P; Chetrit A; Ben-Bassat I
Leuk Res; 1998 Nov; 22(11):997-1002. PubMed ID: 9783801
[TBL] [Abstract][Full Text] [Related]
7. MACOP-B vs F-MACHOP regimen in the treatment of high-grade non-Hodgkin's lymphomas.
Mazza P; Zinzani PL; Martelli M; Fiacchini M; Bocchia M; Pileri S; Falini B; Martelli MF; Amadori S; Papa G
Leuk Lymphoma; 1995 Feb; 16(5-6):457-63. PubMed ID: 7540460
[TBL] [Abstract][Full Text] [Related]
8. A phase II multicenter trial of high-dose sequential chemotherapy and peripheral blood stem cell transplantation as initial therapy for patients with high-risk non-Hodgkin's lymphoma.
Schenkein DP; Roitman D; Miller KB; Morelli J; Stadtmauer E; Pecora AL; Cassileth P; Fernandez H; Cooper BW; Kutteh L; Lazarus HM
Biol Blood Marrow Transplant; 1997 Oct; 3(4):210-6. PubMed ID: 9360783
[TBL] [Abstract][Full Text] [Related]
9. Intensive weekly combination chemotherapy for patients with intermediate-grade and high-grade non-Hodgkin's lymphoma.
Sweetenham JW; Mead GM; Whitehouse JM
J Clin Oncol; 1991 Dec; 9(12):2202-9. PubMed ID: 1720454
[TBL] [Abstract][Full Text] [Related]
10. MACOP-B chemotherapy for the treatment of high grade and intermediate grade non Hodgkin's lymphoma.
Oster W; Forsthuber T; Hennekeuser HH; Gamm H; Lindemann A; Schmitz G; Fuhr HG; Hinterberger R; Kreiter H; Thoenes W
Blut; 1990 Jan; 60(1):23-7. PubMed ID: 1688725
[TBL] [Abstract][Full Text] [Related]
11. Intensive treatment of AIDS-related non-Hodgkin's lymphomas with the MACOP-B protocol.
Schürmann D; Grünewald T; Weiss R; Jautzke G; Pohle HD; Ruf B
Eur J Haematol; 1995 Feb; 54(2):73-7. PubMed ID: 7535244
[TBL] [Abstract][Full Text] [Related]
12. Multidrug resistance (MDR-1) expression in AIDS-related lymphomas.
Tulpule A; Sherrod A; Dharmapala D; Young LL; Espina BM; Sanchez MN; Gill PS; Levine AM
Leuk Res; 2002 Feb; 26(2):121-7. PubMed ID: 11755462
[TBL] [Abstract][Full Text] [Related]
13. Human immunodeficiency virus-associated diffuse non-Hodgkin's lymphoma in Venezuelan patients: treatment with full-dose cyclophosphamide-doxorubicin-vincristine-prednisone without routine use of granulocyte-colony stimulating factor.
Hernàndez DE; Hernàndez AE
Eur J Cancer Care (Engl); 2006 Dec; 15(5):493-6. PubMed ID: 17177909
[TBL] [Abstract][Full Text] [Related]
14. AIDS-related systemic non-Hodgkin's lymphoma at a large community program.
Vilchez RA; Kozinetz CA; Jorgensen JL; Kroll MH; Butel JS
AIDS Res Hum Retroviruses; 2002 Mar; 18(4):237-42. PubMed ID: 11860669
[TBL] [Abstract][Full Text] [Related]
15. EORTC study of non-Hodgkin's lymphoma: phase III study comparing CHVmP-VB and ProMACE-MOPP in patients with stage II, III, and IV intermediate- and high-grade lymphoma.
Somers R; Carde P; Thomas J; Tirelli U; Keuning JJ; Bron D; Delmer A; de Bock R; De Wolf-Peeters C; Keunig JJ
Ann Oncol; 1994; 5 Suppl 2():85-9. PubMed ID: 7515651
[TBL] [Abstract][Full Text] [Related]
16. Hodgkin's disease and non-Hodgkin's lymphoma in an HIV positive patient.
Lichtman SM; Brody J; Kaplan MH; Susin M; Koduru P; Goh JC
Leuk Lymphoma; 1993 Mar; 9(4-5):393-8. PubMed ID: 7688628
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of m-BACOD and granulocyte macrophage colony stimulating factor in HIV-associated non-Hodgkin's lymphoma.
Walsh C; Wernz JC; Levine A; Rarick M; Willson E; Melendez D; Bonnem E; Thompson J; Shelton B
J Acquir Immune Defic Syndr (1988); 1993 Mar; 6(3):265-71. PubMed ID: 7680712
[TBL] [Abstract][Full Text] [Related]
18. Non-Hodgkin's lymphoma in Saudi Arabia: prognostic factors and an analysis of the outcome of combination chemotherapy only, for both localized and advanced disease.
Ibrahim EM; Satti MB; Al-Idrissi HY; Al-Mulhim FA; Abssod GH; Abdel Jabar A
Eur J Cancer Clin Oncol; 1988 Mar; 24(3):391-401. PubMed ID: 2454821
[TBL] [Abstract][Full Text] [Related]
19. MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.
Sertoli MR; Santini G; Chisesi T; Congiu AM; Rubagotti A; Contu A; Salvagno L; Coser P; Porcellini A; Vespignani M
J Clin Oncol; 1994 Jul; 12(7):1366-74. PubMed ID: 7517442
[TBL] [Abstract][Full Text] [Related]
20. Long-term follow-up of non-Hodgkin's lymphoma patients treated with ProMACE-CytaBOM: an effective regimen for the intermediate grade subtype.
Marotta G; Bigazzi C; Bocchia M; Forconi F; Lauria F
Haematologica; 1998 Sep; 83(9):853-4. PubMed ID: 9825583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
